CSIMarket
 
Tonix Pharmaceuticals Holding Corp   (TNXP)
Other Ticker:  
 
 
Price: $0.3696 $-0.01 -2.274%
Day's High: $0.383 Week Perf: 7.35 %
Day's Low: $ 0.35 30 Day Perf: 15.5 %
Volume (M): 1,662 52 Wk High: $ 2.24
Volume (M$): $ 614 52 Wk Avg: $0.83
Open: $0.38 52 Wk Low: $0.26



 Market Capitalization (Millions $) 6
 Shares Outstanding (Millions) 15
 Employees -
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -117
 Cash Flow (TTM) (Millions $) -111
 Capital Exp. (TTM) (Millions $) 15

Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for psychiatric and neurological disorders. The company's lead product candidate, TNX-102 SL, is a sublingual tablet formulation of cyclobenzaprine being developed for the treatment of posttraumatic stress disorder (PTSD), fibromyalgia, and agitation in Alzheimer's disease. Tonix also has a pipeline of other product candidates targeting conditions such as migraine, cocaine dependence, and tick-borne diseases. The company utilizes a proprietary platform technology called Tonix Translational Medicine (TTM) to design new drug products with improved safety, efficacy, and pharmacokinetic properties.


   Company Address: 26 Main Street Chatham 7928 NJ
   Company Phone Number: 799-9155   Stock Exchange / Ticker: NASDAQ TNXP
   TNXP is expected to report next financial results on March 12, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

A Pathway to Prevention: TNX-1500's Potential in Reducing Kidney Transplant Rejection

Published Wed, Feb 28 2024 1:01 PM UTC

Tonix Pharmaceuticals Progresses in the Development of TNX-1500 and Its Potential Impact on Kidney Transplant RejectionWith the increasing demand for organ transplantation worldwide, finding effective ways to prevent graft rejection is crucial. Tonix Pharmaceuticals recently completed the clinical stage of its Phase 1 trial for TNX-1500, a promising Fc-modified humanized ant...

Clinical Study

Positive Results from Clinical Pharmacokinetic Bridging Study of Tonmya Support Development and Partnering in Japan and China

Published Tue, Feb 27 2024 1:01 PM UTC

Tonix Pharmaceuticals recently announced positive results from a clinical pharmacokinetic bridging study of Tonmya, a potential treatment for posttraumatic stress disorder (PTSD). The study aimed to support the development and partnering of Tonmya in Japan and China. The company plans to file a Clinical Trial Notification (CTN) in Japan and an Investigational New Drug (IND) ...

Clinical Study

Tonix Pharmaceuticals Reports Positive Phase 3 Results for Tonmya in Fibromyalgia Trial and Plans NDA Submission

Published Wed, Feb 14 2024 1:00 PM UTC

Tonix Pharmaceuticals, a leading biopharmaceutical company, recently hosted a KOL webinar discussing the positive results from the Phase 3 clinical trial of their drug Tonmya for the treatment of fibromyalgia. The company plans to file a New Drug Application (NDA) for FDA approval in the second half of 2024. The webinar highlighted the broad-spectrum activity of Tonmya, whic...

Licensing Agreement

TNX-102 SL: A Promising Solution for Acute Stress Reaction, PTSD, and Fibromyalgia

Published Mon, Feb 12 2024 1:00 PM UTC

The recent announcement by Tonix Pharmaceuticals regarding the FDA Investigational New Drug (IND) clearance for their trial of TNX-102 SL has sparked considerable interest in the medical community. This groundbreaking development aims to address the reduction of Acute Stress Reaction (ASR) and prevention of Post-Traumatic Stress Disorder (PTSD), offering new hope for individ...

Clinical Study

Exploring the Intersection of Fibromyalgia and Long COVID: Disruptive Discoveries by Tonix Pharmaceuticals Define a New Therapeutic Horizon

Published Wed, Jan 31 2024 12:00 PM UTC

In a significant revelation underlining the intersection of fibromyalgia and long COVID, Tonix Pharmaceuticals has recently announced its research findings. The reported study indicates that pre-existing fibromyalgia-type symptoms could potentially increase the risk of developing post-acute sequelae of SARS-CoV-2 infection (PASC), also known as long COVID. This pioneering re...






 

Tonix Pharmaceuticals Holding's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com